{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:23:47Z","timestamp":1794072227672,"version":"4.8.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST110-2628-B-039-005"],"award-info":[{"award-number":["MOST110-2628-B-039-005"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 111-2823-8-039-001"],"award-info":[{"award-number":["MOST 111-2823-8-039-001"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST110-2314-B-039-032"],"award-info":[{"award-number":["MOST110-2314-B-039-032"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["DMR-114-068"],"award-info":[{"award-number":["DMR-114-068"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Enolase 1 (ENO1) is a glycolytic enzyme involved in tumor progression that performs a variety of classical and nonclassical functions. However, the mechanism by which it promotes tumor progression is still not fully understood. Here, we revealed that TGF\u03b21\/Smad3 signaling triggered the symmetric dimethylation of arginine (SDMA) on ENO1 by protein arginine methyltransferase 5 (PRMT5), leading to membranous ENO1 translocation. Surface ENO1 interacts with monocarboxylate transporter 4 (MCT4) for lactate secretion, which recruits M2 macrophages and promotes an immunosuppressive tumor microenvironment (TME). Targeting surface ENO1 with HuL001, a first-in-class humanized antibody, significantly reduced glycolysis, decreased extracellular lactate accumulation, reprogrammed macrophage polarization and inhibited tumor growth and distant metastasis. Moreover, targeting surface ENO1 significantly increased the therapeutic response to radiotherapy and delayed tumor regrowth by increasing antitumoral M1 macrophages and cytotoxic CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells infiltration within TME. These results indicated that targeting surface ENO1 remodeled the tumor microenvironment and provided better therapeutic effects to radiotherapy in poorly immunogenic colorectal cancer (CRC) and triple-negative breast cancer (TNBC).\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08416-7","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:35:17Z","timestamp":1770010517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeting ENO1 reprograms macrophage polarization to trigger antitumor immunity and improves the therapeutic effect of radiotherapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Yu-Sen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ze","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhen-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ching","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Tung","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao-Wei","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yao","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-An","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-I","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7162-2566","authenticated-orcid":false,"given":"K. S. Clifford","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0266-3233","authenticated-orcid":false,"given":"Kevin Chih-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"8416_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21:687\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1860.","journal-title":"Clin Cancer Res"},{"key":"8416_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"key":"8416_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1003466.","journal-title":"N Engl J Med"},{"key":"8416_CR4","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376:2415\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1613493.","journal-title":"N Engl J Med"},{"key":"8416_CR5","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"key":"8416_CR6","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1158\/1535-7163.MCT-21-0041","volume":"20","author":"RW Lentz","year":"2021","unstructured":"Lentz RW, Colton MD, Mitra SS, Messersmith WA. Innate immune checkpoint inhibitors: the next breakthrough in medical oncology?. Mol Cancer Ther. 2021;20:961\u201374. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0041.","journal-title":"Mol Cancer Ther"},{"key":"8416_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059.","journal-title":"Cancer Discov"},{"key":"8416_CR8","doi-asserted-by":"publisher","unstructured":"Babl N, Decking SM, Voll F, Althammer M, Sala-Hojman A, Ferretti R, et al. MCT4 blockade increases the efficacy of immune checkpoint blockade. J Immunother Cancer. 2023;11. https:\/\/doi.org\/10.1136\/jitc-2023-007349.","DOI":"10.1136\/jitc-2023-007349"},{"key":"8416_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/imr.12846","volume":"295","author":"PJ Siska","year":"2020","unstructured":"Siska PJ, Singer K, Evert K, Renner K, Kreutz M. The immunological Warburg effect: can a metabolic-tumor-stroma score (MeTS) guide cancer immunotherapy?. Immunol Rev. 2020;295:187\u2013202. https:\/\/doi.org\/10.1111\/imr.12846.","journal-title":"Immunol Rev"},{"key":"8416_CR10","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.ccell.2023.05.015","volume":"41","author":"Y Qian","year":"2023","unstructured":"Qian Y, Galan-Cobo A, Guijarro I, Dang M, Molkentine D, Poteete A, et al. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer Cell. 2023;41:1363\u201380.e7. https:\/\/doi.org\/10.1016\/j.ccell.2023.05.015.","journal-title":"Cancer Cell"},{"key":"8416_CR11","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/0008-5472.CAN-14-3511","volume":"75","author":"C Vanpouille-Box","year":"2015","unstructured":"Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, et al. TGFbeta is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 2015;75:2232\u201342. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3511.","journal-title":"Cancer Res"},{"key":"8416_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104745","volume":"155","author":"B Farhood","year":"2020","unstructured":"Farhood B, Khodamoradi E, Hoseini-Ghahfarokhi M, Motevaseli E, Mirtavoos-Mahyari H, Eleojo Musa A, et al. TGF-beta in radiotherapy: mechanisms of tumor resistance and normal tissues injury. Pharmacol Res. 2020;155:104745. https:\/\/doi.org\/10.1016\/j.phrs.2020.104745.","journal-title":"Pharmacol Res"},{"key":"8416_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.aninu.2016.02.005","volume":"2","author":"H Ji","year":"2016","unstructured":"Ji H, Wang J, Guo J, Li Y, Lian S, Guo W, et al. Progress in the biological function of alpha-enolase. Anim Nutr. 2016;2:12\u20137. https:\/\/doi.org\/10.1016\/j.aninu.2016.02.005.","journal-title":"Anim Nutr"},{"key":"8416_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02085-22","volume":"10","author":"L Li","year":"2022","unstructured":"Li L, Lu H, Zhang X, Whiteway M, Wu H, Tan S, et al. Baicalein acts against candida albicans by targeting Eno1 and inhibiting glycolysis. Microbiol Spectr. 2022;10:e0208522. https:\/\/doi.org\/10.1128\/spectrum.02085-22.","journal-title":"Microbiol Spectr"},{"key":"8416_CR15","doi-asserted-by":"publisher","first-page":"8112","DOI":"10.7150\/thno.54961","volume":"11","author":"T Deng","year":"2021","unstructured":"Deng T, Shen P, Li A, Zhang Z, Yang H, Deng X, et al. CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer. Theranostics. 2021;11:8112\u201328. https:\/\/doi.org\/10.7150\/thno.54961.","journal-title":"Theranostics"},{"key":"8416_CR16","first-page":"3641","volume":"9","author":"YS Chang","year":"2003","unstructured":"Chang YS, Wu W, Walsh G, Hong WK, Mao L. Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin Cancer Res. 2003;9:3641\u20134.","journal-title":"Clin Cancer Res"},{"key":"8416_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03087-4","volume":"11","author":"T Yang","year":"2020","unstructured":"Yang T, Shu X, Zhang HW, Sun LX, Yu L, Liu J, et al. Enolase 1 regulates stem cell-like properties in gastric cancer cells by stimulating glycolysis. Cell Death Dis. 2020;11:870. https:\/\/doi.org\/10.1038\/s41419-020-03087-4.","journal-title":"Cell Death Dis"},{"key":"8416_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10549-009-0492-0","volume":"121","author":"SH Tu","year":"2010","unstructured":"Tu SH, Chang CC, Chen CS, Tam KW, Wang YJ, Lee CH, et al. Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010;121:539\u201353. https:\/\/doi.org\/10.1007\/s10549-009-0492-0.","journal-title":"Breast Cancer Res Treat"},{"key":"8416_CR19","first-page":"4470","volume":"11","author":"L Wang","year":"2019","unstructured":"Wang L, Bi R, Yin H, Liu H, Li L. ENO1 silencing impaires hypoxia-induced gemcitabine chemoresistance associated with redox modulation in pancreatic cancer cells. Am J Transl Res. 2019;11:4470\u201380.","journal-title":"Am J Transl Res"},{"key":"8416_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1013035","volume":"12","author":"J Gu","year":"2022","unstructured":"Gu J, Zhong K, Wang L, Ni H, Zhao Y, Wang X, et al. ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway. Front Oncol. 2022;12:1013035. https:\/\/doi.org\/10.3389\/fonc.2022.1013035.","journal-title":"Front Oncol"},{"key":"8416_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/d41573-020-00210-0","volume":"20","author":"S Crunkhorn","year":"2021","unstructured":"Crunkhorn S. Inhibiting enolase eradicates tumours. Nat Rev Drug Discov. 2021;20:20 https:\/\/doi.org\/10.1038\/d41573-020-00210-0.","journal-title":"Nat Rev Drug Discov"},{"key":"8416_CR22","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1038\/s41388-020-1172-0","volume":"39","author":"A Ray","year":"2020","unstructured":"Ray A, Song Y, Du T, Chauhan D, Anderson KC. Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma. Oncogene. 2020;39:2786\u201396. https:\/\/doi.org\/10.1038\/s41388-020-1172-0.","journal-title":"Oncogene"},{"key":"8416_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-016-0385-8","volume":"10","author":"M Principe","year":"2017","unstructured":"Principe M, Borgoni S, Cascione M, Chattaragada MS, Ferri-Borgogno S, Capello M, et al. Alpha-enolase (ENO1) controls alpha v\/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. J Hematol Oncol. 2017;10:16 https:\/\/doi.org\/10.1186\/s13045-016-0385-8.","journal-title":"J Hematol Oncol"},{"key":"8416_CR24","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1158\/1535-7163.MCT-21-0285","volume":"21","author":"ML Chen","year":"2022","unstructured":"Chen ML, Yuan TT, Chuang CF, Huang YT, Chung IC, Huang WC. A novel enolase-1 antibody targets multiple interacting players in the tumor microenvironment of advanced prostate cancer. Mol Cancer Ther. 2022;21:1337\u201347. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0285.","journal-title":"Mol Cancer Ther"},{"key":"8416_CR25","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1182\/blood-2008-08-170837","volume":"113","author":"M Wygrecka","year":"2009","unstructured":"Wygrecka M, Marsh LM, Morty RE, Henneke I, Guenther A, Lohmeyer J, et al. Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood. 2009;113:5588\u201398. https:\/\/doi.org\/10.1182\/blood-2008-08-170837.","journal-title":"Blood"},{"key":"8416_CR26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.omto.2021.12.026","volume":"24","author":"CK Huang","year":"2022","unstructured":"Huang CK, Sun Y, Lv L, Ping Y. ENO1 and cancer. Mol Ther Oncolytics. 2022;24:288\u201398. https:\/\/doi.org\/10.1016\/j.omto.2021.12.026.","journal-title":"Mol Ther Oncolytics"},{"key":"8416_CR27","doi-asserted-by":"publisher","first-page":"e69354","DOI":"10.1371\/journal.pone.0069354","volume":"8","author":"KC Hsiao","year":"2013","unstructured":"Hsiao KC, Shih NY, Fang HL, Huang TS, Kuo CC, Chu PY, et al. Surface alpha-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target. PLoS ONE. 2013;8:e69354. https:\/\/doi.org\/10.1371\/journal.pone.0069354.","journal-title":"PLoS ONE"},{"key":"8416_CR28","doi-asserted-by":"publisher","first-page":"11098","DOI":"10.18632\/oncotarget.3572","volume":"6","author":"M Principe","year":"2015","unstructured":"Principe M, Ceruti P, Shih NY, Chattaragada MS, Rolla S, Conti L, et al. Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells. Oncotarget. 2015;6:11098\u2013113. https:\/\/doi.org\/10.18632\/oncotarget.3572.","journal-title":"Oncotarget"},{"key":"8416_CR29","doi-asserted-by":"publisher","unstructured":"Chung IC, Huang WC, Huang YT, Chen ML, Tsai AW, Wu PY, et al. Unrevealed roles of extracellular enolase\u20111 (ENO1) in promoting glycolysis and pro\u2011cancer activities in multiple myeloma via hypoxia\u2011inducible factor 1alpha. Oncol Rep. 2023;50. https:\/\/doi.org\/10.3892\/or.2023.8642.","DOI":"10.3892\/or.2023.8642"},{"key":"8416_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215795","volume":"543","author":"TW Chen","year":"2022","unstructured":"Chen TW, Hung WZ, Chiang SF, Chen WT, Ke TW, Liang JA, et al. Dual inhibition of TGFbeta signaling and CSF1\/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1. Cancer Lett. 2022;543:215795. https:\/\/doi.org\/10.1016\/j.canlet.2022.215795.","journal-title":"Cancer Lett"},{"key":"8416_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00262-024-03692-8","volume":"73","author":"JY Chen","year":"2024","unstructured":"Chen JY, Lin PY, Hong WZ, Yang PC, Chiang SF, Chang HY, et al. Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy. Cancer Immunol Immunother. 2024;73:92. https:\/\/doi.org\/10.1007\/s00262-024-03692-8.","journal-title":"Cancer Immunol Immunother"},{"key":"8416_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06408-5","volume":"15","author":"KC Huang","year":"2024","unstructured":"Huang KC, Chiang SF, Lin PC, Hong WZ, Yang PC, Chang HP, et al. TNFalpha modulates PANX1 activation to promote ATP release and enhance P2RX7-mediated antitumor immune responses after chemotherapy in colorectal cancer. Cell Death Dis. 2024;15:24. https:\/\/doi.org\/10.1038\/s41419-023-06408-5.","journal-title":"Cell Death Dis"},{"key":"8416_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01132-x","volume":"10","author":"TW Ke","year":"2025","unstructured":"Ke TW, Chen CY, Chen WT, Tsai YY, Chiang SF, Huang CH, et al. Targeting B7-H3 enhances the efficacy of neoantigen-based cancer vaccine in combination with radiotherapy. NPJ Vaccines. 2025;10:80. https:\/\/doi.org\/10.1038\/s41541-025-01132-x.","journal-title":"NPJ Vaccines"},{"key":"8416_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1051\/bmdcn\/2018080104","volume":"8","author":"X Wang","year":"2018","unstructured":"Wang X, Sheu JJ, Lai MT, Yin-Yi Chang C, Sheng X, Wei L, et al. RSF-1 overexpression determines cancer progression and drug resistance in cervical cancer. Biomedicine. 2018;8:4. https:\/\/doi.org\/10.1051\/bmdcn\/2018080104.","journal-title":"Biomedicine"},{"key":"8416_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.7603\/s40681-015-0005-x","volume":"5","author":"TY Lin","year":"2015","unstructured":"Lin TY, Fan CW, Maa MC, Leu TH. Lipopolysaccharide-promoted proliferation of Caco-2 cells is mediated by c-Src induction and ERK activation. Biomedicine. 2015;5:5. https:\/\/doi.org\/10.7603\/s40681-015-0005-x.","journal-title":"Biomedicine"},{"key":"8416_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1019-6","volume":"9","author":"CY Huang","year":"2018","unstructured":"Huang CY, Chiang SF, Chen WT, Ke TW, Chen TW, You YS, et al. HMGB1 promotes ERK-mediated mitochondrial Drp1 phosphorylation for chemoresistance through RAGE in colorectal cancer. Cell Death Dis. 2018;9:1004. https:\/\/doi.org\/10.1038\/s41419-018-1019-6.","journal-title":"Cell Death Dis"},{"key":"8416_CR37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.21873\/anticanres.16870","volume":"44","author":"TW Ke","year":"2024","unstructured":"Ke TW, Zwane ST, Chiang SF, Chen TW, Yang PC, Chen LC, et al. Prognostic value of immune cells subsets within the tumor microenvironment in patients with rectal adenocarcinoma. Anticancer Res. 2024;44:787\u201396. https:\/\/doi.org\/10.21873\/anticanres.16870.","journal-title":"Anticancer Res"},{"key":"8416_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1158\/2326-6066.CIR-22-0318","volume":"11","author":"KC Huang","year":"2023","unstructured":"Huang KC, Lai CY, Hung WZ, Chang HY, Lin PC, Chiang SF, et al. A novel engineered AAV-based neoantigen vaccine in combination with radiotherapy eradicates tumors. Cancer Immunol Res. 2023;11:123\u201336. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0318.","journal-title":"Cancer Immunol Res"},{"key":"8416_CR39","doi-asserted-by":"publisher","unstructured":"Huang KC, Chiang SF, Chang HY, Hong WZ, Chen JY, Lee PC, et al. Colorectal cancer-specific IFNbeta delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2023-008515.","DOI":"10.1136\/jitc-2023-008515"},{"key":"8416_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07912-6","volume":"16","author":"JY Chen","year":"2025","unstructured":"Chen JY, Ke TW, Chiang SF, Hong WZ, Chang HY, Liang JA, et al. CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancer. Cell Death Dis. 2025;16:584. https:\/\/doi.org\/10.1038\/s41419-025-07912-6.","journal-title":"Cell Death Dis"},{"key":"8416_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218132","volume":"637","author":"YY Tsai","year":"2026","unstructured":"Tsai YY, Chang HY, Hong WZ, Chen JY, Chiang SF, Lin YS, et al. Targeting DRP1 promotes radiotherapy-induced antitumor immunity via mitochondrial DNA-mediated cGAS-STING signaling in KRAS-mutated colorectal cancer. Cancer Lett. 2026;637:218132. https:\/\/doi.org\/10.1016\/j.canlet.2025.218132.","journal-title":"Cancer Lett"},{"key":"8416_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116958","volume":"177","author":"KC Huang","year":"2024","unstructured":"Huang KC, Ke TW, Lai CY, Hong WZ, Chang HY, Lee CY, et al. Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy. Biomed Pharmacother. 2024;177:116958. https:\/\/doi.org\/10.1016\/j.biopha.2024.116958.","journal-title":"Biomed Pharmacother"},{"key":"8416_CR43","doi-asserted-by":"publisher","first-page":"6481","DOI":"10.1002\/jcp.30323","volume":"236","author":"KC Huang","year":"2021","unstructured":"Huang KC, Chiang SF, Yang PC, Ke TW, Chen TW, Lin CY, et al. ATAD3A stabilizes GRP78 to suppress ER stress for acquired chemoresistance in colorectal cancer. J Cell Physiol. 2021;236:6481\u201395. https:\/\/doi.org\/10.1002\/jcp.30323.","journal-title":"J Cell Physiol"},{"key":"8416_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1989790","volume":"10","author":"KC Huang","year":"2021","unstructured":"Huang KC, Chiang SF, Ke TW, Chen TW, Hu CH, Yang PC, et al. DNMT1 constrains IFNbeta-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy. Oncoimmunology. 2021;10:1989790. https:\/\/doi.org\/10.1080\/2162402X.2021.1989790.","journal-title":"Oncoimmunology"},{"key":"8416_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05069-0","volume":"13","author":"KC Huang","year":"2022","unstructured":"Huang KC, Chiang SF, Chang HY, Chen WT, Yang PC, Chen TW, et al. Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade. Cell Death Dis. 2022;13:610. https:\/\/doi.org\/10.1038\/s41419-022-05069-0.","journal-title":"Cell Death Dis"},{"key":"8416_CR46","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.bbadis.2018.02.021","volume":"1864","author":"D Zakrzewicz","year":"2018","unstructured":"Zakrzewicz D, Didiasova M, Kruger M, Giaimo BD, Borggrefe T, Mieth M, et al. Protein arginine methyltransferase 5 mediates enolase-1 cell surface trafficking in human lung adenocarcinoma cells. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1816\u201327. https:\/\/doi.org\/10.1016\/j.bbadis.2018.02.021.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"8416_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.apsb.2022.05.019","volume":"13","author":"M Sun","year":"2023","unstructured":"Sun M, Li L, Niu Y, Wang Y, Yan Q, Xie F, et al. PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD\/ENO1 mediated cell metabolism. Acta Pharm Sin B. 2023;13:157\u201373. https:\/\/doi.org\/10.1016\/j.apsb.2022.05.019.","journal-title":"Acta Pharm Sin B"},{"key":"8416_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi8602","volume":"7","author":"JT Noe","year":"2021","unstructured":"Noe JT, Rendon BE, Geller AE, Conroy LR, Morrissey SM, Young LEA, et al. Lactate supports a metabolic-epigenetic link in macrophage polarization. Sci Adv. 2021;7:eabi8602. https:\/\/doi.org\/10.1126\/sciadv.abi8602.","journal-title":"Sci Adv"},{"key":"8416_CR49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10989-016-9555-3","volume":"23","author":"M Purwin","year":"2017","unstructured":"Purwin M, Markowska A, Bruzgo I, Rusak T, Surazynski A, Jaworowska U, et al. Peptides with 6-aminohexanoic acid: synthesis and evaluation as plasmin inhibitors. Int J Pept Res Ther. 2017;23:235\u201345. https:\/\/doi.org\/10.1007\/s10989-016-9555-3.","journal-title":"Int J Pept Res Ther"},{"key":"8416_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.614726","volume":"11","author":"FA Almaguel","year":"2020","unstructured":"Almaguel FA, Sanchez TW, Ortiz-Hernandez GL, Casiano CA. Alpha-enolase: emerging tumor-associated antigen, cancer biomarker, and oncotherapeutic target. Front Genet. 2020;11:614726. https:\/\/doi.org\/10.3389\/fgene.2020.614726.","journal-title":"Front Genet"},{"key":"8416_CR51","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fcell.2019.00061","volume":"7","author":"M Didiasova","year":"2019","unstructured":"Didiasova M, Schaefer L, Wygrecka M. When place matters: shuttling of enolase-1 across cellular compartments. Front Cell Dev Biol. 2019;7:61. https:\/\/doi.org\/10.3389\/fcell.2019.00061.","journal-title":"Front Cell Dev Biol"},{"key":"8416_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-015-0117-5","volume":"8","author":"QF Fu","year":"2015","unstructured":"Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, Dong SW, et al. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K\/AKT pathway. J Hematol Oncol. 2015;8:22. https:\/\/doi.org\/10.1186\/s13045-015-0117-5.","journal-title":"J Hematol Oncol"},{"key":"8416_CR53","doi-asserted-by":"publisher","first-page":"47691","DOI":"10.18632\/oncotarget.17868","volume":"8","author":"X Qian","year":"2017","unstructured":"Qian X, Xu W, Xu J, Shi Q, Li J, Weng Y, et al. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer. Oncotarget. 2017;8:47691\u2013708. https:\/\/doi.org\/10.18632\/oncotarget.17868.","journal-title":"Oncotarget"},{"key":"8416_CR54","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3892\/ol.2020.12003","volume":"20","author":"L Zhang","year":"2020","unstructured":"Zhang L, Lu T, Yang Y, Hu L. alpha-enolase is highly expressed in liver cancer and promotes cancer cell invasion and metastasis. Oncol Lett. 2020;20:152. https:\/\/doi.org\/10.3892\/ol.2020.12003.","journal-title":"Oncol Lett"},{"key":"8416_CR55","doi-asserted-by":"publisher","unstructured":"Mandili G, Curcio C, Bulfamante S, Follia L, Ferrero G, Mazza E, et al. In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. J Immunother Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-001071.","DOI":"10.1136\/jitc-2020-001071"},{"key":"8416_CR56","doi-asserted-by":"publisher","unstructured":"Cappello P, Curcio C, Mandili G, Roux C, Bulfamante S, Novelli F. Next generation immunotherapy for pancreatic cancer: DNA vaccination is seeking new combo partners. Cancers. 2018;10. https:\/\/doi.org\/10.3390\/cancers10020051.","DOI":"10.3390\/cancers10020051"},{"key":"8416_CR57","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fonc.2017.00286","volume":"7","author":"L Iommarini","year":"2017","unstructured":"Iommarini L, Porcelli AM, Gasparre G, Kurelac I. Non-canonical mechanisms regulating hypoxia-inducible factor 1 alpha in cancer. Front Oncol. 2017;7:286. https:\/\/doi.org\/10.3389\/fonc.2017.00286.","journal-title":"Front Oncol"},{"key":"8416_CR58","doi-asserted-by":"publisher","first-page":"11983","DOI":"10.1074\/jbc.M114.598425","volume":"290","author":"M Didiasova","year":"2015","unstructured":"Didiasova M, Zakrzewicz D, Magdolen V, Nagaraj C, Balint Z, Rohde M, et al. STIM1\/ORAI1-mediated Ca2+ influx regulates enolase-1 exteriorization. J Biol Chem. 2015;290:11983\u201399. https:\/\/doi.org\/10.1074\/jbc.M114.598425.","journal-title":"J Biol Chem"},{"key":"8416_CR59","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.7150\/ijbs.63556","volume":"17","author":"G Qiao","year":"2021","unstructured":"Qiao G, Wu A, Chen X, Tian Y, Lin X. Enolase 1, a moonlighting protein, as a potential target for cancer treatment. Int J Biol Sci. 2021;17:3981\u201392. https:\/\/doi.org\/10.7150\/ijbs.63556.","journal-title":"Int J Biol Sci"},{"key":"8416_CR60","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/s41388-023-02674-x","volume":"42","author":"A Liu","year":"2023","unstructured":"Liu A, Yu C, Qiu C, Wu Q, Huang C, Li X, et al. PRMT5 methylating SMAD4 activates TGF-beta signaling and promotes colorectal cancer metastasis. Oncogene. 2023;42:1572\u201384. https:\/\/doi.org\/10.1038\/s41388-023-02674-x.","journal-title":"Oncogene"},{"key":"8416_CR61","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/onc.2016.205","volume":"36","author":"H Chen","year":"2017","unstructured":"Chen H, Lorton B, Gupta V, Shechter D. A TGFbeta-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression. Oncogene. 2017;36:373\u201386. https:\/\/doi.org\/10.1038\/onc.2016.205.","journal-title":"Oncogene"},{"key":"8416_CR62","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","volume":"9","author":"KG de la Cruz-Lopez","year":"2019","unstructured":"de la Cruz-Lopez KG, Castro-Munoz LJ, Reyes-Hernandez DO, Garcia-Carranca A, Manzo-Merino J. Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front Oncol. 2019;9:1143. https:\/\/doi.org\/10.3389\/fonc.2019.01143.","journal-title":"Front Oncol"},{"key":"8416_CR63","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24:657\u201371. https:\/\/doi.org\/10.1016\/j.cmet.2016.08.011.","journal-title":"Cell Metab"},{"key":"8416_CR64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fnut.2014.00027","volume":"1","author":"ML Goodwin","year":"2014","unstructured":"Goodwin ML, Gladden LB, Nijsten MW, Jones KB. Lactate and cancer: revisiting the warburg effect in an era of lactate shuttling. Front Nutr. 2014;1:27. https:\/\/doi.org\/10.3389\/fnut.2014.00027.","journal-title":"Front Nutr"},{"key":"8416_CR65","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.18632\/oncotarget.6798","volume":"7","author":"M Capello","year":"2016","unstructured":"Capello M, Ferri-Borgogno S, Riganti C, Chattaragada MS, Principe M, Roux C, et al. Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. Oncotarget. 2016;7:5598\u2013612. https:\/\/doi.org\/10.18632\/oncotarget.6798.","journal-title":"Oncotarget"},{"key":"8416_CR66","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1093\/emboj\/19.15.3896","volume":"19","author":"P Kirk","year":"2000","unstructured":"Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000;19:3896\u2013904. https:\/\/doi.org\/10.1093\/emboj\/19.15.3896.","journal-title":"EMBO J"},{"key":"8416_CR67","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1038\/s41423-021-00710-y","volume":"18","author":"C Zhang","year":"2021","unstructured":"Zhang C, Zhang K, Gu J, Ge D. ENO1 promotes antitumor immunity by destabilizing PD-L1 in NSCLC. Cell Mol Immunol. 2021;18:2045\u20137. https:\/\/doi.org\/10.1038\/s41423-021-00710-y.","journal-title":"Cell Mol Immunol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08416-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08416-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08416-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:41:05Z","timestamp":1770298865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08416-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8416"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08416-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WCH and TTY were employed from HuniLife Biotechnology. The other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were carried out in accordance with the relevant ethical guidelines and regulations. The tissue collection study was reviewed and approved by the Internal Review Board (IRB) of China Medical University Hospital [Protocol number: CMUH105-REC2-072]. All the experimental procedures and animal protocols used were approved by the China Medical University Institutional Animal Care and Use Committee (Protocol No. CMUIACUC-2023-114) and followed all the relevant ethical regulations. All procedures were designed in accordance with the ethical standards of the China Medical University Institutional Animal Care and Use Committee to minimize the suffering and number of animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all human participants or their legal guardians in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"194"}}